Export region

Tablet coating material exported to Latin America

Strong national regulators with detailed dossier requirements and established generic industries.

Written by the Rglax Pharma technical team, who formulate and manufacture every grade named on this page at our WHO-GMP works in Tahliwal, Una (drug manufacturing licence NNZ/23/238). Reviewed 3 September 2026. Licences and certificates.

Send an export enquiry +91 98821 30484

A smooth glossy white coated tablet — The markets we supply across Latin America, and the route from Tahliwal. Not a statement of registration in any market.

What this region runs

Brazil and Mexico both carry large domestic generic industries with demanding national dossier requirements. ANVISA in particular expects excipient documentation in depth, and the registration timeline reflects that.

Why our range fits it

This is the region where documentation, rather than formulation, is most often the deciding factor. It is worth establishing early exactly what your regulatory affairs team needs from an excipient supplier, because the answer here is more detailed than in most markets we serve.

What to send us

Start with your documentation list rather than the technical requirement. We would rather tell you at the outset what we can and cannot supply for an ANVISA or COFEPRIS submission than find out at dossier stage.

Market facts

Markets: Brazil, Mexico, Colombia, Peru, Chile, Argentina
Pharmacopoeia: USP predominantly, with the Brazilian Pharmacopoeia applying in Brazil.
Exported from: Plot No. 30, Industrial Area Tahliwal, Himachal Pradesh, India
Licence: NNZ/23/238
Compliance: WHO-GMP Compliance Unit
DMF: U.S.-DMF applied

Regulators you would be working under

ANVISA, Brazil
COFEPRIS, Mexico
INVIMA, Colombia
DIGEMID, Peru

Listed so you know the framework we would be supplying into. It is not a claim that we hold a registration or approval with any of them.

Grades

The 4 grades most asked for in Latin America.

Chosen against the climate zone, the product mix and the documentation expectations of the region. Each links to its full page, with the process parameters it was developed on.

ECM-RP347 Enteric coating
Enteric coat, methacrylic base, non-aqueous
Solvent base methacrylic enteric film for the Pantoprazole group.
Methacrylic base enteric coating applied from a non-aqueous system, formulated for the Pantoprazole group and other dissolution critical enteric tablets. It runs best over a transparent seal coat such as SC-401, which protects the acid labile core.
Base ·
Non-aqueous (solvent)
Finish ·
Enteric film, gastro resistant
Formulated against ·
Pantoprazole group
AQ-ZWt10 Film coating
Aqueous film coat, extra white
Water base extra white film coat for cores that show through a standard white.
Aqueous extra white film coat developed for tablets where the core colour bleeds through a conventional white film. Calcium and Azithromycin cores are the usual cases. It gives higher opacity at the same build-up.
Base ·
Aqueous
Finish ·
Extra white, high opacity
Formulated against ·
Calcium, Azithromycin
MB 31RP Moisture barrier
Moisture barrier for multivitamin and ferrous tablets
Solvent base barrier film for hygroscopic multivitamin and iron formulations.
Solvent base moisture barrier film coat for Multivitamin and Ferrous group tablets. It protects the core from moisture pick-up and from the colour change that follows it on shelf.
Base ·
Non-aqueous (solvent)
Finish ·
Colour or white, moisture barrier
Formulated against ·
Multivitamins, Ferrous group
SR100 Sustained release
Sustained release material
Ready-mix blend for extended release solid dosage forms.
Sustained release material for controlled release drug delivery systems. It is supplied as a ready-mix so the release profile is reproducible batch to batch without in-house polymer blending.
Base ·
Dry blend
Finish ·
Functional release layer